Genprex, Inc. (GNPX) stock
GNPXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.90−0.18 (-8.65%)
Close on Nov 16, 2026Market cap $1.56MP/E –Yield –
Genprex r&d expenses
Research and development expenses are spending on new products and technology.
Genprex's R&D Expenses for the twelve months ending Jun 30, 2026 was $9.82M, down 7.7% year over year. For fiscal 2025 it was $9.43M, down 10.5% from the year before. The highest annual figure on record is $17.62M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.43M | -10.5% |
| FY2024 | Dec 31, 2024 | $10.54M | -40.2% |
| FY2023 | Dec 31, 2023 | $17.62M | +53.1% |
| FY2022 | Dec 31, 2022 | $11.51M | +28.3% |
| FY2021 | Dec 31, 2021 | $8.97M | +22.8% |
| FY2020 | Dec 31, 2020 | $7.30M | +271.3% |
| FY2019 | Dec 31, 2019 | $1.97M | +102.5% |
| FY2018 | Dec 31, 2018 | $971.43K | +235.1% |
| FY2017 | Dec 31, 2017 | $289.93K | -18.3% |
| FY2016 | Dec 31, 2016 | $354.88K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.68M | +7.4% |
| Q1 FY2026 | Mar 31, 2026 | $2.75M | +8.1% |
| Q4 FY2025 | Dec 31, 2025 | $2.20M | -22.6% |
| Q3 FY2025 | Sep 30, 2025 | $2.19M | -20.4% |
| Q2 FY2025 | Jun 30, 2025 | $2.50M | +50.0% |
| Q1 FY2025 | Mar 31, 2025 | $2.54M | -22.4% |
| Q4 FY2024 | Dec 31, 2024 | $2.84M | -23.6% |
| Q3 FY2024 | Sep 30, 2024 | $2.76M | -40.3% |
| Q2 FY2024 | Jun 30, 2024 | $1.67M | -58.1% |
| Q1 FY2024 | Mar 31, 2024 | $3.27M | -38.3% |
| Q4 FY2023 | Dec 31, 2023 | $3.71M | +9.7% |
| Q3 FY2023 | Sep 30, 2023 | $4.62M | +46.2% |
| Q2 FY2023 | Jun 30, 2023 | $3.98M | +35.9% |
| Q1 FY2023 | Mar 31, 2023 | $5.31M | +160.3% |
| Q4 FY2022 | Dec 31, 2022 | $3.39M | -11.9% |
| Q3 FY2022 | Sep 30, 2022 | $3.16M | +120.5% |
| Q2 FY2022 | Jun 30, 2022 | $2.93M | +91.8% |
| Q1 FY2022 | Mar 31, 2022 | $2.04M | -0.0% |
| Q4 FY2021 | Dec 31, 2021 | $3.84M | +65.7% |
| Q3 FY2021 | Sep 30, 2021 | $1.43M | +6.1% |
| Q2 FY2021 | Jun 30, 2021 | $1.53M | -29.2% |
| Q1 FY2021 | Mar 31, 2021 | $2.04M | +38.1% |
| Q4 FY2020 | Dec 31, 2020 | $2.32M | +373.8% |
| Q3 FY2020 | Sep 30, 2020 | $1.35M | +188.9% |
| Q2 FY2020 | Jun 30, 2020 | $2.16M | +329.4% |
| Q1 FY2020 | Mar 31, 2020 | $1.48M | +190.9% |
| Q4 FY2019 | Dec 31, 2019 | $489.58K | +54.4% |
| Q3 FY2019 | Sep 30, 2019 | $467.34K | -4.6% |
| Q2 FY2019 | Jun 30, 2019 | $502.04K | +344.4% |
| Q1 FY2019 | Mar 31, 2019 | $508.04K | +884.2% |
| Q4 FY2018 | Dec 31, 2018 | $317.15K | +419.3% |
| Q3 FY2018 | Sep 30, 2018 | $489.69K | +782.1% |
| Q2 FY2018 | Jun 30, 2018 | $112.97K | +7.6% |
| Q1 FY2018 | Mar 31, 2018 | $51.62K | -24.5% |
| Q4 FY2017 | Dec 31, 2017 | $61.07K | -52.8% |
| Q3 FY2017 | Sep 30, 2017 | $55.52K | -38.2% |
| Q2 FY2017 | Jun 30, 2017 | $104.98K | – |
| Q1 FY2017 | Mar 31, 2017 | $68.36K | – |
| Q4 FY2016 | Dec 31, 2016 | $129.34K | – |
| Q3 FY2016 | Sep 30, 2016 | $89.90K | – |
See a number that looks wrong?